En español



  1. Academy for Educational Development (AED), Hepatitis C virus and HIV coinfection. Washington, DC, 2002. Data retrieved 7/20/2010 from http://www.cdc.gov/idu/hepatitis/hepc_and_hiv_co.pdf (PDF, 45KB).
  2. Alessi, S.M.; Hanson, T.; Wieners, M.; and Petry, N.M. Low-cost contingency management in community clinics: Delivering incentives partially in group therapy. Experimental and Clinical Psychopharmacol 15(3):293-300, 2007.
  3. Des Jarlais, D.C.; Arasteh, K.; Perlis, T.; Hagan, H.; Abdul- Quader, A.; Heckathorn, D.D.; McKnight, C.; Bramson, H.; Nemeth, C.; Torian, L.V.; and Friedman, S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 21(2):231-235, 2007.
  4. Gold, M.S. Cocaine (and crack): Clinical aspects. In: Lowinson, J.H., ed. Substance Abuse: A Comprehensive Textbook, 4th edition, Baltimore: Williams & Wilkins, pp. 218-251, 2005.
  5. Hagan, H.; Des Jarlais, D.C.; Stern, R.; Lelutiu- Weinberger, C.; Scheinmann, R.; Strauss, S.; and Flom, P.L. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 18:341-351, 2007.
  6. Johnston, L.D.; O'Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009. DHHS Pub. No. 10-7583. Bethesda, MD: NIDA, 2010.
  7. Karila, L.; Gorelick, D.; Weinstein, A.; Noble, F.; Benyamina, A.; Coscas, S.; Blecha, L.; Lowenstein, W.; Martinot, J.L.; Reynaud, M.; and Lepine, J.P. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol, 11(3):425-438, 2007.
  8. Orson F.M.; Kinsey, B.M.; Singh, R.A.K.; Wu, Y.; and Kosten, T.R. Vaccines for cocaine abuse. Human vaccines, 5(4):194-199, 2009.
  9. Sokoloff, P.; Diaz, J.; Le Foll, B.; Guillin, O.; Leriche, L.; Bezard, E.; and Gross, C. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5(1):25-43, 2006.
  10. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, Detailed Tables: National Estimates of Drug-Related Emergency Department Visits 2004-2008. Data retrieved 7/20/2010 from http://www.samhsa.gov/data/DAWN.aspx.
  11. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. DHHS Pub. No. SMA 09-4443, Rockville, MD: SAMHSA, 2009.
  12. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights-2007. National Admissions to Substance Abuse Treatment Services. DHHS Pub. No. SMA 09-4360, Rockville, MD: SAMHSA, 2009.
  13. Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; and O'Brien, C.P. The status of disulfiram: A half of a century later. J Clin Psychopharmacol 26(3):290-302, 2006.
  14. Tseng, F.C.; O'Brien, T.R.; Zhang, M.; Kral, A.H.; Ortiz-Conde, B.A.; Lorvick, J.; Busch, M.P.; and Edlin, B.R. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 46(3):666-671, 2007.
  15. Volkow, N.D.; Wang, G.-J.; Fowler, J.S.; Logan, J.; Gatley, S.J.; Hitzemann, R.; Chen, A.D.; Dewey, S.L.; and Pappas, N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386(6627):830-833, 1997.

This page was last updated September 2010

Get this Publication

NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.